No Data
No Data
Edgewise Rated as a New Hold at Stifel on a Balanced Risk-reward Setup
Edgewise Therapeutics Names Behrad Derakhshan as COO; Shares Fall
Edgewise Therapeutics: Semigran, Current CDO, Will Depart and Serve as Clinical Adviser to Ensure Smooth Transition >EWTX
Edgewise Therapeutics: Behrad Derakhshan, Ph.D. Promoted to Oper Chief >EWTX
Express News | Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
Stifel Maintains Edgewise Therapeutics(EWTX.US) With Hold Rating, Maintains Target Price $30